Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Durvalumab and Chemotherapy for Resected Small Cell Lung Cancer
NCT07149363Phase 2Recruiting
- Sponsor
- Alliance Foundation Trials
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by Alliance Foundation Trials. Started Feb 2026; status: recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07149363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07149363.